Merus NV « Terug naar discussie overzicht

Merus NV forum geopend

1.045 Posts, Pagina: « 1 2 3 4 5 6 ... 48 49 50 51 52 53 | Laatste
Ik heb gezien dat er abstract gepubliceerd worden, maar wat stond daar dan in dat nog niet bekend was? 38% stijging!

Titel van abstract: Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Ik vind het altijd lastig om te beoordelen hoe positief of negatief zoiets is. Het medicijn wordt samen met een ander medicijn gebruikt. Welk positief effect heeft het medicijn van Merus dan? Met andere hoeveel beter zijn de resultaten met de toevoeging van Petosemtamab.
Passo dello Stelvio
Het gaat in de studie om het gecombineerde effect van beide middelen.

Pembrolizumab is namelijk al in farmotherapeutisch kompas beschreven als middel voor HNNSCC:

"Hoofd-halsplaveiselcelcarcinoom (HNSCC)
recidiverend of gemetastaseerd HNSCC mét PD-L1-expressie met TPS = 50% en met progressie tijdens of na platinumbevattende chemotherapie bij volwassenen, als monotherapie;
eerstelijnsbehandeling van gemetastaseerd of inoperabel recidiverend HNSCC bij volwassenen bij wie de tumoren een PD-L1-expressie vertonen met een 'combined positive score' (CPS) = 1, als monotherapie of in combinatie met 5-fluoro-uracil (systemisch) en platinabevattende chemotherapie."

De respons van pembro alleen op HNSCC ken ik niet , maar Merus zal geen paper tonen als de resultaten van de combi niet beter zijn dan pembro alleen
Passo dello Stelvio
vd site van Merus geplukt:
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

“MCLA-145 as monotherapy or with pembrolizumab appears to have a manageable safety profile and early clinical activity in these difficult to treat cancers. Our biomarker data suggest that both dose and less frequent administration may be important determinants of clinical activity, and we are encouraged by the progress we are making with MCLA-145,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “As our company is now increasingly focused on our lead asset petosemtamab and plan to initiate phase 3 trials in head and neck cancer later this year, we aim to advance clinical development of MCLA-145 in the context of a potential collaboration.”

MCLA-145 (CD137 x PD-L1 Biclonics®): Solid Tumors
Interim data included in the presentation describe data from patients (pts) with advanced/metastatic solid tumors who received MCLA-145 Q2W in 28 day cycles or every three weeks (Q3W) in 21 day cycles. Pts treated with the combination of MCLA-145 and pembrolizumab had cancers that either relapsed after PD-(L)1 therapies or were immunotherapy (IO) naïve.

Rapid oral presentation title: Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
Observations in the presentation include:

As of a January 3, 2024 data cutoff date, 72 pts with multiple cancer types were treated; 25% of pts had non-small cell lung cancer (NSCLC)

All patients were heavily pre-treated with a median of 3 prior therapies; prior IO in 49% of the monotherapy pts and 100% of the combination pts

In monotherapy, 52 pts with a variety of tumor types and treated at different dose levels were evaluable for response

5 partial responses (PRs) were observed at different dose levels in glioblastoma (ongoing as of the cutoff date for >3 years), sarcoma (pretreated with pazopanib and gemcitabine/docetaxel), cervical, anal, and gastric cancer by Response Evaluation Criteria in Solid Tumors v1.1. per investigator assessment

2 of 6 pts PRs (33%) were observed for pts treated at the recommended dose for expansion (RDE), 40 mg Q3W

3 of 6 PRs (50%) were observed for pts with evaluable baseline tumor CD8 T-cell density of = 250 cells/mm2 responded

In combination with pembrolizumab, 19 pts with a variety of tumor types and treated at different dose levels were evaluable for response

1 PR in Merkel cell carcinoma was observed at 25 mg Q3W

1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W

3 pts were continuing combination therapy at cutoff date

MCLA-145 monotherapy or in combination with pembrolizumab had a well-tolerated and manageable safety profile at the RDE, 40mg Q3W

Shifting from Q2W to Q3W resulted in a 50% reduction of Grade (G) =3 treatment-emergent adverse events in both monotherapy and combination therapy

Liver toxicity, a common CD137 related adverse event, was controlled with no G4 events observed at Q3W

The full presentation is available on the Merus website.
1.045 Posts, Pagina: « 1 2 3 4 5 6 ... 48 49 50 51 52 53 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum


Vertraagd 22 jul 2024 22:00
Koers 55,780
Verschil +0,480 (+0,87%)
Hoog 56,620
Laag 55,120
Volume 453.070
Volume gemiddeld 1.076.474
Volume gisteren 709.553

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront